RxDoctor Payments Data

James Razi, MD

Family Medicine · Live Oak, FLNPI 1902874233

Payments from drug & device makers

$1,337in general payments, 2019–2025

Across 73 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$276
  • Boehringer Ingelheim$217
  • Novo Nordisk$148
  • Supernus Pharmaceuticals, Inc.$110
  • Lilly USA, LLC$84
  • Amgen$68
  • plus $435 from 15 others

What the payments were for

  • Food & beverage$1,337100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,337 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$2,303
Medicare patients
93
Services billed
164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$88,935
EliquisApixaban89$81,207
FarxigaDapagliflozin Propanediol53$62,235
JardianceEmpagliflozin49$56,479
MounjaroTirzepatide48$53,529
JanuviaSitagliptin Phosphate44$47,746
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$31,026
JanumetSitagliptin Phos/Metformin Hcl23$24,641
LinzessLinaclotide23$23,272
Tresiba Flextouch U-100Insulin Degludec33$17,008
UbrelvyUbrogepant14$15,011
XareltoRivaroxaban12$14,065
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$13,379
Spiriva RespimatTiotropium Bromide18$9,268
Breo ElliptaFluticasone/Vilanterol12$9,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$148$88,93587 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$14$82,63097 claims
PfizerEliquis$31$81,20789 claims
Boehringer IngelheimJardiance, Spiriva Respimat$217$65,74667 claims
Lilly USA, LLCMounjaro$84$53,52948 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$49$43,10364 claims
AbbVieLinzess, Ubrelvy$276$38,28337 claims
Johnson & JohnsonXarelto$19$14,06512 claims
Sanofi-aventis U.S. LLCLantus$39$4,84617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Live Oak

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →